Britannia Life Sciences Inc.
BLAB
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -5.90M | -5.40M | -3.99M | -3.54M | 1.26M |
| Total Depreciation and Amortization | 171.30K | 181.80K | 195.90K | 207.30K | 150.90K |
| Total Amortization of Deferred Charges | 114.20K | 80.30K | 53.90K | 36.30K | 52.40K |
| Total Other Non-Cash Items | 6.04M | 5.20M | 4.10M | 3.88M | -643.30K |
| Change in Net Operating Assets | 381.90K | 683.00K | 743.80K | 964.00K | 823.00K |
| Cash from Operations | 806.80K | 735.60K | 1.10M | 1.55M | 1.65M |
| Capital Expenditure | -20.60K | -16.30K | 70.30K | -100.10K | -105.10K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 1.80K | -685.20K | -685.20K | -810.80K | -812.60K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -317.90K | -261.70K | -213.30K | -152.00K | -81.60K |
| Cash from Investing | -336.70K | -963.20K | -828.20K | -1.06M | -999.30K |
| Total Debt Issued | 798.50K | 798.50K | 27.00K | 27.00K | 23.40K |
| Total Debt Repaid | -2.26M | -2.17M | -2.06M | -2.00M | -894.70K |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -791.70K |
| Cash from Financing | -1.07M | -1.01M | -1.50M | -1.46M | -1.23M |
| Foreign Exchange rate Adjustments | 60.80K | 101.60K | -14.30K | 33.30K | 53.80K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -534.30K | -1.13M | -1.24M | -940.90K | -532.00K |